Biotech News - Vertex Pharmaceuticals Incorporated (Public, NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated (Public, NASDAQ:VRTX)

Vertex presents mixed results in hepatitis C drug
30th October 2006
By Victoria Harrison
Vertex has presented mixed results from its phase Ib trial of its
hepatitis C drug, saying that some patients still had the virus when
combined with ribavirin.
The study examined Vertex's investigational hepatitis C virus
protease inhibitor, telaprevir in combination with pegylated
interferon (peg-IFN) with or without ribavirin.

The hepatitis C virus was suppressed in patients when pegylated
interferon was added to telaprevir in the phase Ib clinical study

More here: http://www.pharmaceutical-business-review.com/article_news.asp?guid=47B35064-373A-4E2F-A667-8B3538B4911F

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/